A paradigm shift in patent law?

March 31, 2006

Recent disputes between research-based pharma companies and generics have addressed the viability of use patents in PMNOC proceedings. Bill Richardson of McCarthy TÃ©trault LLP examines the cases and asks whether the Regulations need to be changed

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login

Managing IP Correspondent

Each week Managing IP speaks to a different IP practitioner about their life and career

Max Walters, December 11, 2023

Sources debate the implications of an opinion by Delaware’s chief judge Colm Connolly that lambasted the NPE IP Edge

Rani Mehta, December 08, 2023

Five partners reveal how delays in examining trademark applications are affecting their advice to clients and how they pitch new work

Rani Mehta, December 08, 2023

We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP

Sukanya Sarkar, December 08, 2023

Partners at Quinn Emanuel explain how walkie-talkie and real-estate analogies helped them win over a jury at the Eastern District of Texas

Rani Mehta, December 07, 2023

The heads of Malaysian firm HHQ’s new technology practice group say they can be frontline advisers on the intersection between AI, blockchain, and IP

Sukanya Sarkar, December 07, 2023

Darren Jiron, Finnegan’s managing partner in London, discusses the firm’s growth plans and misconceptions about US firm culture

Rory O’Neill, December 07, 2023

The EMEA region research cycle has commenced - do not miss this opportunity to nominate your work from 2023!

John Harrison, December 07, 2023

A former partner at Stroock & Stroock & Lavan, which voted to dissolve in October, has joined McCarter & English

Rani Mehta, December 07, 2023

As ChatGPT celebrates its first birthday, we are still grappling with a multitude of IP concerns

Max Walters, December 06, 2023